Acadia Pharmaceuticals 2025 Q3 Earnings Record Net Income Surges 119%

Acadia Pharmaceuticals (ACAD) delivered Q3 2025 results that exceeded expectations, with revenue and net income both rising sharply. The company raised its full-year revenue guidance, reflecting strong demand for its core products and improved profitability.

Revenue

, driven entirely by product sales. The company’s flagship drugs, NUPLAZID and DAYBUE, , respectively, .

Earnings/Net Income

, . This marked a record high for the company’s Q3 net income in over two decades, bolstered by a tax benefit from the One Big Beautiful Bill Act.

Price Action

Despite robust earnings, , .

Post-Earnings Price Action Review

A strategy of buying ACAD shares on the day of its earnings announcement and holding for 30 days has historically yielded positive returns. Over the past three years, , .

CEO Commentary

. She emphasized momentum in new prescriptions and international expansion, , including ACP-204 and trofinetide.

Guidance

, . , . The updated guidance includes U.S. and non-U.S. sales, reflecting expanded operations.

Additional News

Acadia recently announced strategic leadership changes, including Catherine Owen Adams’ appointment as Chairperson of the Biotechnology Innovation Organization (BIO)’s Emerging Companies section and Konstantina Katcheves as Chief Business and Strategy Officer. These moves aim to strengthen global business development and pipeline expansion. Additionally, Adams underscored the company’s commitment to advancing its clinical trials, such as Phase 2/3 studies for ACP-204 and trofinetide, to solidify its position in neurology and rare diseases.

Article Polishing

The report has been revised for clarity, ensuring smooth transitions between sections and consistent terminology. All numerical data and factual claims remain unchanged. Formatting adheres to the original structure, with bold headings and precise use of placeholders.